Navigation Links
Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
Date:8/30/2010

10, 2010.

"We decided to have our common stock listed on the Tel Aviv Stock Exchange, in addition to the current listing on the NYSE Amex, after experiencing significant interest regarding our company from Israeli investors.  We believe that the dual listing will result in a larger, more diverse group of investors in our shares," said David Aviezer, Ph.D., Protalix's President and Chief Executive Officer. "We expect that the listing on the Tel Aviv Stock Exchange will result in increased investor interest in our shares without affecting the rules and regulations of the U.S. Securities and Exchange Commission and the NYSE Amex to which we are currently subject."

"We are very pleased to welcome Protalix to the Tel Aviv Stock Exchange," said Ester Levanon, CEO of the Tel Aviv Stock Exchange.  "The TASE is home to Israel's most innovative companies among them over 50 biotechnology companies and 51 dual-listed companies.  The listing of Protalix, a leading company in the biotechnology sector, reflects the international leading position of the Tel Aviv Stock Exchange in the Hi-Tech and biotech industries"

The Company will continue to be subject to the rules and regulations of the NYSE Amex and the U.S. Securities and Exchange Commission.
Dual listing on the Tel Aviv Stock Exchange is allowed under Israeli law without any additional regulatory requirements for companies whose shares are listed on certain exchanges outside of Israel, including the NYSE Amex.

Trading on the Tel Aviv Stock Exchange occurs Sunday through Thursday from 9:45 am to 4:30 pm Israel time, except on trading holidays recognized by the Tel Aviv Stock Exchange.
The TASE Clearing House is electronically linked to the Depository Trust Company, a subsidiary of the Depository Trust & Clearing Corporation, to automate the cross-border settlement of shares listed on both the TASE and a U.S. stock exchange.

ABOUT PROTALIX Pro
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Protalix Announces Successful GMP Manufacturing Audit by Israels Ministry of Health
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Northwest Biotherapeutics Secures $700,000 Equity Financing
5. Oxygen Biotherapeutics, Inc. Expands Board of Directors
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
11. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth ... the Renaissance Waterfront Hotel in Boston, MA. The ... at the current strategies and innovations for optimizing bioprocesses ... in the field will reveal how their work has ... specificity and efficiency. , “In this age of rapid ...
(Date:5/16/2013)...  The registration deadline has been extended until May ... National Conference, the premier conference for bioscience financial officers. ... Hilton San Diego Bayfront. "We are ... want to make sure as many people as possible ... Roberts , Chief Financial Officer of Mast Therapeutics, ...
(Date:5/16/2013)... On average, developing a new drug takes over ... this investment, less than 10% of drugs make it ... trial design optimally structured to balance time, cost and ... Sax, Global Head of the Center for Drug Development ... and technology in upfront clinical trial planning and design ...
(Date:5/16/2013)... May 16, 2013 BioInformatics LLC New ... & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) ... of suppliers in the primary cells market continues to ... types are used most often, how satisfied scientists are ... size and anticipated growth rate. ,  , Additionally, ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... the University of Pittsburgh have made advances in better ... we know it, according to a study published in ... W. Vincent Liu, associate professor of physics in ... researchers from the University of Maryland and the University ...
... (OTCBB: GNLK.OB, "the Company," or "GeneLink"), a ... the quarter ended September 30th, 2011. Bernard ... a business development potential, the third quarter has been ... Company.  The Company continues to make progress towards the ...
... Calif., Nov. 21, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), ... for the three and nine months ended September 30, ... increase adoption of its SmartChip System. "During ... commercial strategy to address the rapidly changing needs of ...
Cached Biology Technology:Pitt discoveries in quantum physics could change face of technology 2GeneLink Marketing Efforts Poised to Show Results 2GeneLink Marketing Efforts Poised to Show Results 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8
(Date:5/16/2013)... University scientists have shown a gene involved in neurodegenerative ... function of the circadian clock. , In a ... the gene, called Ataxin-2, keeps the clock responsible for ... gene, the rhythm of the fruit fly,s sleep-wake cycle ... difficult for the fly. , The discovery is ...
(Date:5/16/2013)... endothelium, the cellular layer lining the body,s blood ... hundred nanometers in thickness, this super-tenuous structure routinely ... compression to create a unique and highly dynamic ... tissues from the body,s circulatory system. , It,s ... must be physically breached to enable immune ...
(Date:5/16/2013)... Why do so many sports players and athletes choose ... new study to be published in Psychological Science ... suggests that it may have to do with their ... scientist Daniel Farrelly of the University of Sunderland and ... color in a competitive task had higher testosterone levels ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4High-testosterone competitors more likely to choose red 2
... radiation delivered by a robotic arm eradicated lung tumors ... medical physicist Cihat Ozhasoglu, Ph.D. of the University of ... the 48th Annual Meeting of the American Association of ... too early to determine the technique's long-term effectiveness, Ozhasoglu ...
... at the Salk Institute for Biological Studies have identified ... store or burn fat, a discovery that suggests new ... diseases. , Genetically engineered mice, in which the ... ravages of a high-fat diet, the Salk team led ...
... at the University of California, San Diego (UCSD) School ... by cycles of liver cell death and renewal. , ... in advance of publication in the journal Proceedings of ... JNK1-mediated cell death and compensatory proliferation. The findings ...
Cached Biology News:Radiation-armed robot rapidly destroys human lung tumors 2Chewing up a key regulator of fat synthesis keeps mice lean despite a high-fat diet 2Chewing up a key regulator of fat synthesis keeps mice lean despite a high-fat diet 3Cycles of cell death, proliferation key to liver cancer 2
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Biology Products: